Key Takeaways

  • Emmecell has dosed the first patient in its randomized, placebo-controlled phase 2 EMERALD trial evaluating EO2002 for corneal edema

  • The study will assess two cell doses, with the primary endpoint measuring at least a 15-letter improvement in BCVA at 26 weeks

  • EO2002 uses magnetically guided corneal endothelial cells delivered through a single intracameral injection as a potential alternative to corneal transplantation

Emmecell has announced dosing of the first patient in its phase 2 EMERALD clinical trial evaluating EO2002, an investigational allogeneic human corneal endothelial cell therapy for adults with corneal edema secondary to corneal endothelial dysfunction.

The multicenter, randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of EO2002 in patients with conditions including Fuchs endothelial corneal dystrophy and pseudophakic bullous keratopathy.

EO2002 is administered through a single intracameral injection using Emmecell's Magnetic Cell Delivery platform, which combines magnetically labeled corneal endothelial cells with an external magnetic patch designed to guide cells toward the corneal endothelium and improve retention.

The investigational therapy is being developed as a minimally invasive alternative to corneal transplantation.

The EMERALD study (NCT07729137) will evaluate two doses of EO2002, with participants randomized to receive a single intracameral injection of 150,000 cells, 500,000 cells, or placebo.

The primary endpoint is the proportion of study eyes achieving at least a 15-letter improvement in best-corrected visual acuity from baseline at 26 weeks. Secondary assessments include changes in visual acuity, central corneal thickness, and safety, with participants followed for 52 weeks.

Emmecell intends EMERALD to serve as the first of two clinical trials in its planned registrational program.

“Starting dosing in EMERALD is an important step toward evaluating a different treatment approach for patients with corneal endothelial disease,” said Ramin Valian, Chief Executive Officer of Emmecell. “Our goal is to restore corneal function through a single injection and reduce the burden of transplant surgery. This randomized, placebo-controlled study is designed to generate the evidence needed to evaluate that potential and guide the next stage of EO2002’s development. We thank the patients, investigators and study teams making this work possible.”

Corneal endothelial dysfunction can result in fluid accumulation, corneal swelling, and impaired vision. Advanced cases frequently require endothelial keratoplasty, which depends on donor corneal tissue. EO2002 is designed to restore corneal endothelial function without transplanting a donor tissue graft.

The FDA granted EO2002 Regenerative Medicine Advanced Therapy designation in July 2026.